Physician profile
Andrew Oehler
NPI 1336482421
$844.36
in general payments reported to CMS, 2019-2025
10 companies · $500 in 2025
The $500 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.24 · 2020: $14.18 · 2021: $95.17 · 2022: $77.20 · 2024: $144 · 2025: $500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $645.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $644.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $270.72 | 2024-2025 | Evkeeza |
| Novartis Pharmaceuticals Corporation | $194.99 | 2021-2025 | |
| Heartflow, INC. | $165.67 | 2025 | |
| Ionis Pharmaceuticals, INC. | $68.88 | 2025 | |
| Amgen INC. | $59.98 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $32.94 | 2021 | |
| Boston Scientific Corporation | $19.62 | 2022 | |
| Angiodynamics, INC. | $18.32 | 2025 | Bioflo |
| Lantheus Medical Imaging, INC. | $13.24 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Oehler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.